Ciraparantag
Clinical data | |
---|---|
Other names | PER977; N1,N1′-[Piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Onset of action | 10 min |
Duration of action | 24 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H48N12O2 |
Molar mass | 512.708 g·mol−1 |
3D model (JSmol) | |
| |
|
Ciraparantag (aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, and heparins (including fondaparinux, low molecular weight heparins (LMWH), and unfractionated heparin).[1][2]
Medical uses
[edit]Ciraparantag significantly reverses anticoagulation induced by a therapeutic dose of edoxaban within 10 minutes following injection.[3] This return to normal haemostasis persists over 24 hours following a single intravenous dose of the drug.[4] In addition to edoxaban, it also reverses the actions of LMWH and dabigatran.[5]
Pharmacology
[edit]Mechanism of action
[edit]According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds and charge-charge interactions [3] from or to various parts of the molecule:[1]
Hydrogen bonds | Rivaroxaban | Apixaban | Edoxaban | Dabigatran | Heparins |
---|---|---|---|---|---|
Guanidine part | |||||
α-Amino group | |||||
Amide nitrogen | |||||
Amide oxygen |
Chemistry
[edit]Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.[1]
See also
[edit]References
[edit]- ^ a b c Schubert-Zsilavecz M, Wurglics M (Fall 2015). Neue Arzneimittel (in German).
- ^ Ansell JE (February 2016). "Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants". Journal of Thrombosis and Thrombolysis. 41 (2): 248–52. doi:10.1007/s11239-015-1288-1. PMID 26449414. S2CID 7364744.
- ^ a b Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. (January 2017). "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban". Thrombosis and Haemostasis. 117 (2): 238–245. doi:10.1160/TH16-03-0224. PMC 6260118. PMID 27853809.
- ^ Laulicht B, Bakhru S, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (June 2013). "Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977". J Thromb Haemost. 11 (suppl 2): 1–84.
- ^ Costin JC, Laulicht B, Bakhru S, Steiner S (March 2015). "PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants". Journal of the American College of Cardiology. 65 (10): A2056. doi:10.1016/S0735-1097(15)62056-3.